NCT01768338 2023-02-10
Recombinant Human IL-18 and Ofatumumab After PBSCT for Lymphoma
Indiana University
Phase 1 Completed
Clinical Trials
6 trialsNCT00107718 2017-07-27
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
GlaxoSmithKline
Phase 2 Completed
NCT00500058 2017-07-26
A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18
GlaxoSmithKline
Phase 1 Completed
NCT00659178 2017-07-21
Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian Cancer
GlaxoSmithKline
Phase 1 Completed
NCT00085878 2008-10-16
Dose-Escalation Study Of SB-485232 Administered As Daily Subcutaneous Injections In Adults With Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT00085904 2008-10-13
Dose-Escalating Study Of SB-485232 Administered Intravenously Every 28 Days To Adults With Solid Tumors Or Lymphomas
GlaxoSmithKline
Phase 1 Completed